Trial Parameters
Brief Summary
The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.
Eligibility Criteria
Inclusion Criteria: * (1) Histologically confirmed relapsed/refractory HL, PMBCL, GZL, and TCL including the below subtypes: * Arm 1: PTCL * Nodal PTCL Peripheral T-cell Lymphoma- Not Otherwise Specified (PTCL-NOS) * Anaplastic Large Cell Lymphoma (ALCL) T-follicular Helper Lymphomas (TFH) and its subtypes including angioimmunoblastic T-cell Lymphoma (AITL) * Extranodal NK/T-cell lymphoma * Subcutaneous Panniculitis T-Cell Lymphoma * Arm 2: CTCL * Mycosis Fungoides * Sezary Syndrome * Arm 3: exploratory cohort * Classic HL * PMBCL * GZL * (2) All patients must have received at least one-line systemic therapy. * Patients with systemic ALCL must have received prior CD30-directed therapy. * Other PTCL subtypes that express CD30 (\>10%), must have received prior CD30-directed therapy. * Special Consideration for CTCL in Arm 2: * Systemic therapies including bexarotene (targretin) are permissible up to 2 weeks prior to enrollment. * Skin directed therapies including light therapy/photothera